Sermorelin Dosage, Reconstitution & Mixing Trends

Explore sermorelin calculator-entry dose, vial-size, BAC-water and self-reported frequency distributions. Research context is separate from live observations.

Anonymized sermorelin calculator entries are summarized by each chart's selected period. Frequency responses come from the separate vial-duration feature. Inputs are not verified administrations or unique people.

What Sermorelin Is

Sermorelin is a growth-hormone-releasing-hormone (GHRH) analog most often sourced for GH-axis and age-related "somatopause" research, frequently stacked with ipamorelin. It ships as a lyophilized powder you reconstitute with bacteriostatic water before use.[1]

Sermorelin binds the GHRH receptor on pituitary somatotrophs to stimulate endogenous pulsatile GH release. Because the GH response is rate-limited by somatostatin tone and pituitary reserve, the negative-feedback architecture remains intact, in contrast to direct recombinant-hGH replacement.

Pediatric GHD trials supported the original approval;[2] subsequent investigator-initiated work has examined sermorelin in age-related GH decline, adult somatopause, and as a less-suppressive alternative to recombinant hGH. The molecule is now widely compounded at 503A pharmacies for off-label adult use.

Originally FDA-approved as Geref (pediatric GHD); discontinued from the U.S. market in 2008. Currently compounded at 503A pharmacies. Research-grade material for non-clinical use.

Sermorelin Research Sources

Sermorelin Dosing Context

Sermorelin has a reported half-life of ~10–20 min. The pharmacokinetic reference models an interval of once daily (before bed); this is not a measured community cadence or a dosing recommendation. Sermorelin is gone within an hour. It works as a discrete pulse that triggers endogenous GH release — no systemic buildup, so consistency of timing matters more than dose accumulation. Pharmacokinetic source: Walker et al. clinical pharmacokinetic studies, 1991. It is catalogued under Muscle Peptides on WPA.

Sermorelin Community Calculator Data

1,631 Sermorelin reconstitution calculations have been logged by the WPA community.

This is the lifetime header population. Each chart and its associated analysis below use their own selected period and denominator; frequency responses are a separate cohort.

These figures come from anonymized WPA peptide calculator sessions, not verified administrations or unique people. Separate modal inputs do not establish a joint protocol. They are community input statistics — not dosing recommendations, and not medical advice.

WPA Analysis

Sermorelin Research Background and Calculator Data

Sermorelin holds an unusual place in the GH-secretagogue family — it is one of only two GHRH analogs ever to have carried an FDA approval (the other being tesamorelin), and the molecule that defined the modern GHRH stimulation test. Sermorelin is GHRH (1-29) NH2, the synthetic acetate salt of the first 29 amino acids of native human growth-hormone-releasing hormone, the same backbone every "Modified GRF 1-29" and CJC-1295 analog is built on. The pivotal product was Geref (Serono), approved by the FDA for pediatric growth hormone deficiency in the 1990s and used clinically through the early 2000s — both as a daily subcutaneous treatment and as a single-dose intravenous diagnostic agent in the GHRH stimulation test, where a measured GH response to an exogenous GHRH bolus distinguishes pituitary GH-axis dysfunction from hypothalamic dysfunction. Geref was withdrawn from the U.S. market in 2008, not for a safety or efficacy concern but because the more potent and convenient recombinant hGH replacement therapies (somatropin, etc.) had become the standard of care for pediatric GHD — sermorelin's indirect mechanism of stimulating endogenous GH release through a daily injection had simply lost its competitive position against the direct hormone-replacement alternative.

The sermorelin researchers buy and use today is the same molecule, typically prepared by U.S. compounding pharmacies under 503A or 503B oversight, and it has retained a meaningful niche in adult GH-axis research and in age-management compounding practice. The published pharmacology is unchanged: a half-life of roughly 10-20 minutes after subcutaneous injection, a clean physiologic GH-pulse stimulus when dosed pre-sleep, and a tolerability profile that the original Geref label characterized as broadly favorable.

Research background is separate from the calculator observations below. Calculator entries do not establish administration, safety, effectiveness, or the reasons for an input.

WPA DOSING INSIGHT

Dose and Frequency Calculator Inputs

The summaries use each chart's own period and, for frequency responses, its dose filter. Separate cohorts must not be combined into a protocol.

WPA RECONSTITUTION INSIGHT

Vial Size and BAC Water Calculator Inputs

Vial-size and BAC-water observations describe separate input distributions, not purchases or verified preparations. Separate modal inputs do not establish a joint protocol.

These figures come from anonymized WPA peptide calculator sessions.

All figures shown are aggregated from anonymized calculator inputs and are provided strictly for independent laboratory research and educational purposes. They are community usage statistics — not dosing recommendations, and not medical advice.